Article info

Original research
A novel Fc-engineered cathepsin D-targeting antibody enhances ADCC, triggers tumor-infiltrating NK cell recruitment, and improves treatment with paclitaxel and enzalutamide in triple-negative breast cancer

Authors

  1. Correspondence to Dr Emmanuelle Liaudet-Coopman; emmanuelle.liaudet-coopman{at}inserm.fr
View Full Text

Citation

Desroys du Roure P, Lajoie L, Mallavialle A, et al
A novel Fc-engineered cathepsin D-targeting antibody enhances ADCC, triggers tumor-infiltrating NK cell recruitment, and improves treatment with paclitaxel and enzalutamide in triple-negative breast cancer

Publication history

  • Accepted December 19, 2023
  • First published January 30, 2024.
Online issue publication 
January 30, 2024
  • Supplementary Data

    This web only file has been produced by the BMJ Publishing Group from an electronic file supplied by the author(s) and has not been edited for content.

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.